Stockreport

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Evogene Ltd. - Ordinary Shares  (EVGN) 
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am Check Earnings Report
US:NYSE Investor Relations: evogene.com/investor-relations
PDF BMC128 was developed by Biomica, Evogene's subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical resultsREHOVOT, Israel and SH [Read more]